Tirzepatide
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Eli Lilly · Phase 2 · Completed · Enrollment 392
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide (TZP) + Mibavademab (MIBA) [Group A] | n/r | n/r | n/r | n/r |
| TZP + Mibavademab-placebo (MIBA-PBO) [Group B] | n/r | n/r | n/r | n/r |
| TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C] | n/r | n/r | n/r | n/r |
| TZP + MIBA [Group D] | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO [Group E] | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO then TZP-PBO + MIBA [Group F] | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO then TZP + MIBA [Group G] | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H] | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]: endpoint not reported
- TZP + Mibavademab-placebo (MIBA-PBO) [Group B]: endpoint not reported
- TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]: endpoint not reported
- TZP + MIBA [Group D]: endpoint not reported
- TZP + MIBA-PBO [Group E]: endpoint not reported
- TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]: endpoint not reported
- TZP + MIBA-PBO then TZP + MIBA [Group G]: endpoint not reported
- TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]: endpoint not reported